Production & Manufacturing

Advanced analytical technologies in pharma impurity testing are transforming how trace contaminants are detected, identified, and controlled across the drug lifecycle. With high-resolution instrumentation, automation, and AI-driven insights, the industry is strengthening precision, data integrity, and patient safety to meet increasingly stringent purity standards.

PFAS regulations in pharmaceutical supply chains are reshaping how critical materials are sourced, validated, and justified amid rising environmental scrutiny. Manufacturers must balance sustainability, regulatory compliance, and material performance to ensure uninterrupted delivery of safe and effective medicines.

Nitrosamine risk mitigation in global pharma manufacturing requires proactive control of chemical pathways, excipients, and operational practices to prevent trace-level carcinogenic impurities. Advanced analytics, rigorous risk assessments, and strengthened GMP frameworks are now essential to ensure long-term product safety and regulatory compliance.

As global pharmaceutical supply chains expand across diverse climates and sourcing regions, the risk of resilient fungal toxins entering drug products has intensified. Effective mycotoxins risk monitoring now demands proactive, data-driven oversight, advanced analytics, and integrated quality frameworks to protect patient safety at every stage of production.

Implementation of a unified data framework serves as the catalyst for modernizing pharmaceutical production, bridging the gap between legacy processes and intelligent automation. By consolidating disparate data streams into a cohesive repository, organizations achieve unprecedented visibility into critical quality attributes and process parameters. This transformation facilitates proactive risk mitigation and ensures that Good Manufacturing Practices are maintained through high-fidelity insights rather than retrospective analysis, ultimately fostering a culture of continuous improvement and operational excellence.

Johnson & Johnson announced that it plans to invest more than $1 billion to construct a new cell therapy facility in Pennsylvania. The move forms part of the company’s broader strategy, unveiled last year, to expand its U.S. manufacturing...

On February 17, 2026, GSK plc announced that the European Commission approves Exdensur - depemokimab in two indications - As an add-on maintenance treatment when it comes to critical asthma with type 2 inflammation that stands characterised by a blood eosinophil...